Unknown

Dataset Information

0

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.


ABSTRACT:

Background

Clostridioides difficile infection is the most common cause of healthcare-associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA polymerase IIIC inhibitor with in vitro activity against C. difficile.

Objectives and methods

Randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of ibezapolstat in healthy volunteers. Microbiome changes associated with ibezapolstat were compared with vancomycin over a 10 day course using shotgun metagenomics.

Results

A total of 62 subjects aged 31 ± 7 years (45% female; average BMI: 25 ± 3 kg/m2) were randomized. Ibezapolstat was well tolerated with a safety signal similar to placebo. Ibezapolstat had minimal systemic absorption with the majority of plasma concentrations less than 1 µg/mL. In the multiday, ascending dose study, ibezapolstat concentrations of 2000 µg/g of stool were observed by Day 2 and for the remainder of the dosing time period. In the multiday, multiple-dose arm, baseline microbiota was comparable between subjects that received ibezapolstat compared with vancomycin. At Day 10 of dosing, differential abundance analysis and β-diversity demonstrated a distinct difference between the microbiome in subjects given vancomycin compared with either dose of ibezapolstat (P = 0.006). α-Diversity changes were characterized as an increase in the Actinobacteria phylum in subjects that received ibezapolstat and an increase in Proteobacteria in subjects given vancomycin.

Conclusions

Ibezapolstat was shown to be safe and well tolerated, with minimal systemic exposure, high stool concentrations and a distinct microbiome profile compared with oral vancomycin. These results support further clinical development of ibezapolstat for patients with C. difficile infection.

SUBMITTER: Garey KW 

PROVIDER: S-EPMC7662179 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.

Garey Kevin W KW   Begum Khurshida K   Lancaster Chris C   Gonzales-Luna Anne A   Bui Dinh D   Mercier Julie J   Seng Yue Corinne C   Ducharme Murray P MP   Hu Ming M   Vince Bradley B   Silverman Michael H MH   Alam M Jahangir MJ   Kankam Martin M  

The Journal of antimicrobial chemotherapy 20201201 12


<h4>Background</h4>Clostridioides difficile infection is the most common cause of healthcare-associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA polymerase IIIC inhibitor with in vitro activity against C. difficile.<h4>Objectives and methods</h4>Randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of ibezapolstat in healthy volunteers. Microbiome changes associated with ibezapolstat were compared with  ...[more]

Similar Datasets

| S-EPMC7548281 | biostudies-literature
| S-EPMC5947602 | biostudies-literature
| S-EPMC8183013 | biostudies-literature
| S-EPMC8815515 | biostudies-literature
| S-EPMC8504836 | biostudies-literature
| S-EPMC9468557 | biostudies-literature
| S-EPMC9203127 | biostudies-literature
| S-EPMC10777847 | biostudies-literature
| S-EPMC5137824 | biostudies-literature
| S-EPMC5114201 | biostudies-literature